FI3155017T3 - Parannettuja peptidilääkkeitä insuliiniresistenssiin - Google Patents
Parannettuja peptidilääkkeitä insuliiniresistenssiin Download PDFInfo
- Publication number
- FI3155017T3 FI3155017T3 FIEP15798956.7T FI15798956T FI3155017T3 FI 3155017 T3 FI3155017 T3 FI 3155017T3 FI 15798956 T FI15798956 T FI 15798956T FI 3155017 T3 FI3155017 T3 FI 3155017T3
- Authority
- FI
- Finland
- Prior art keywords
- lys
- glu
- aspl5
- phe22
- trp25
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 21
- 206010022489 Insulin Resistance Diseases 0.000 title claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims 3
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- -1 cyclic lactam Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C07H13/06—Fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462004156P | 2014-05-28 | 2014-05-28 | |
| PCT/US2015/033042 WO2015184177A1 (en) | 2014-05-28 | 2015-05-28 | Improved peptide pharmaceuticals for insulin resistance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3155017T3 true FI3155017T3 (fi) | 2024-04-17 |
Family
ID=54699825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP15798956.7T FI3155017T3 (fi) | 2014-05-28 | 2015-05-28 | Parannettuja peptidilääkkeitä insuliiniresistenssiin |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US9856306B2 (enExample) |
| EP (2) | EP4397374A3 (enExample) |
| JP (4) | JP6697807B2 (enExample) |
| KR (3) | KR102542164B1 (enExample) |
| CN (5) | CN117582516A (enExample) |
| AU (3) | AU2015266854B2 (enExample) |
| BR (1) | BR112016027595B1 (enExample) |
| CA (1) | CA2949701C (enExample) |
| DK (1) | DK3155017T3 (enExample) |
| ES (1) | ES2985732T3 (enExample) |
| FI (1) | FI3155017T3 (enExample) |
| HU (1) | HUE066179T2 (enExample) |
| IL (3) | IL285613B2 (enExample) |
| MX (2) | MX371033B (enExample) |
| NZ (2) | NZ757113A (enExample) |
| PL (1) | PL3155017T3 (enExample) |
| PT (1) | PT3155017T (enExample) |
| WO (1) | WO2015184177A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2602801C2 (ru) | 2011-05-18 | 2016-11-20 | МЕДЕРИС ДАЙАБИТИЗ, ЭлЭлСи | Пептидные лекарственные препараты с повышенной эффективностью против инсулинорезистентности |
| JP6148228B2 (ja) | 2011-05-18 | 2017-06-14 | ユーメデリス ファーマシューティカルズ，インク． | 改善されたペプチド製剤 |
| EP2922877B1 (en) * | 2012-11-20 | 2018-09-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| EP3653649A1 (en) | 2012-11-20 | 2020-05-20 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for insulin resistance |
| PL3155017T3 (pl) * | 2014-05-28 | 2024-06-17 | Mederis Diabetes, Llc | Ulepszone farmaceutyki peptydowe dla insulinooporności |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| EP3654941A1 (en) | 2017-07-17 | 2020-05-27 | Keith Roizman | Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases |
| EP3735295B1 (en) | 2018-01-03 | 2024-08-21 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for treatment of nash and other disorders |
| KR20220143923A (ko) * | 2020-02-21 | 2022-10-25 | 스핏파이어 파마, 엘엘씨 | Glp-1r 및 gcgr 효능제, 제형 및 사용 방법 |
| CN117202924A (zh) | 2020-12-07 | 2023-12-08 | 斯皮特弗尔制药有限责任公司 | 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法 |
| MX2023006736A (es) * | 2020-12-07 | 2023-08-21 | Spitfire Pharma Llc | Regimenes y metodos terapeuticos para reducir la glucosa en sangre o el peso corporal usando agonistas balanceados de glp-1r y gcgr. |
| CN113461747B (zh) * | 2021-07-12 | 2023-02-03 | 吉林化工学院 | 刺玫果中2个具有降血糖活性的化合物 |
| WO2024239961A1 (zh) * | 2023-05-24 | 2024-11-28 | 联邦生物科技(珠海横琴)有限公司 | 一种胰岛素衍生物及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3219656A (en) | 1963-08-12 | 1965-11-23 | Rohm & Haas | Alkylpolyalkoxyalkyl glucosides and process of preparation therefor |
| US3839318A (en) | 1970-09-27 | 1974-10-01 | Rohm & Haas | Process for preparation of alkyl glucosides and alkyl oligosaccharides |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DK149776C (da) | 1984-01-06 | 1987-04-21 | Orion Yhtymae Oy | Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen |
| AT382381B (de) | 1984-10-02 | 1987-02-25 | Oesterr Zuckerfab Evidenz | Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5252318A (en) | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| US5661130A (en) | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
| JPH1160598A (ja) | 1997-08-15 | 1999-03-02 | Asahi Glass Co Ltd | オピオイド様ペプチド |
| US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
| US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| RU2181729C1 (ru) | 2000-09-20 | 2002-04-27 | Калюжин Олег Витальевич | Производные мурамовой кислоты |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
| US6864069B2 (en) * | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| EP2305311A3 (en) | 2001-10-10 | 2011-07-20 | BioGeneriX AG | Glycoconjugation of peptides |
| US6881829B2 (en) | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
| US20110257096A1 (en) | 2004-08-25 | 2011-10-20 | Aegis Therapeutics, Inc. | Compositions for drug administration |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| ITRM20040607A1 (it) | 2004-12-15 | 2005-03-15 | Biogen S R L | Analoghi della dermorfina ad attivita' analgesica. |
| WO2006096426A2 (en) | 2005-03-03 | 2006-09-14 | The Board Of Trustees Of The University Of Illinois | Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization |
| CA2607566A1 (en) * | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use |
| US7390788B2 (en) | 2005-06-23 | 2008-06-24 | Pert Candace B | Peptide pharmaceutical compositions |
| ES2397289T3 (es) | 2005-09-22 | 2013-03-06 | Biocompatibles Uk Ltd. | Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada |
| WO2007060692A2 (en) | 2005-11-24 | 2007-05-31 | Brain N' Beyond Biotech Pvt. Ltd. | Compositions for increasing bioavailability of peptides or proteins and method thereof |
| US7998927B2 (en) | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US8173594B2 (en) | 2006-06-23 | 2012-05-08 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| WO2008052043A2 (en) | 2006-10-24 | 2008-05-02 | Cogenesys, Inc. | Opioid receptor agonist fusion proteins |
| EP1961765A1 (en) | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| KR20090119876A (ko) | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/ｇｌｐ-1 수용체 공동-항진물질 |
| NZ589847A (en) | 2008-06-17 | 2013-01-25 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
| CA2767792A1 (en) | 2009-07-13 | 2011-01-20 | Zealand Pharma A/S | Acylated glucagon analogues |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| BR112013015389A2 (pt) | 2010-12-22 | 2016-11-22 | Univ Indiana Res & Tech Corp | análogo de glucagon exibindo atividade de receptor gip |
| KR101453037B1 (ko) | 2011-03-23 | 2014-10-21 | 주식회사 엘지화학 | 전극조립체 및 이의 제조방법 |
| RU2602801C2 (ru) * | 2011-05-18 | 2016-11-20 | МЕДЕРИС ДАЙАБИТИЗ, ЭлЭлСи | Пептидные лекарственные препараты с повышенной эффективностью против инсулинорезистентности |
| JP6148228B2 (ja) | 2011-05-18 | 2017-06-14 | ユーメデリス ファーマシューティカルズ，インク． | 改善されたペプチド製剤 |
| EP2922877B1 (en) * | 2012-11-20 | 2018-09-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| EP3653649A1 (en) | 2012-11-20 | 2020-05-20 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for insulin resistance |
| EP2986313B1 (en) * | 2013-04-18 | 2019-06-12 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| PL3155017T3 (pl) | 2014-05-28 | 2024-06-17 | Mederis Diabetes, Llc | Ulepszone farmaceutyki peptydowe dla insulinooporności |
| TN2017000148A1 (en) * | 2014-10-24 | 2018-10-19 | Merck Sharp & Dohme | Co-agonists of the glucagon and glp-1 receptors |
| EP3735295B1 (en) * | 2018-01-03 | 2024-08-21 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for treatment of nash and other disorders |
-
2015
- 2015-05-28 PL PL15798956.7T patent/PL3155017T3/pl unknown
- 2015-05-28 AU AU2015266854A patent/AU2015266854B2/en active Active
- 2015-05-28 CN CN202311098620.9A patent/CN117582516A/zh active Pending
- 2015-05-28 MX MX2016015594A patent/MX371033B/es active IP Right Grant
- 2015-05-28 JP JP2016569787A patent/JP6697807B2/ja active Active
- 2015-05-28 CA CA2949701A patent/CA2949701C/en active Active
- 2015-05-28 CN CN202311098595.4A patent/CN117180445A/zh active Pending
- 2015-05-28 KR KR1020167036463A patent/KR102542164B1/ko active Active
- 2015-05-28 CN CN202011222645.1A patent/CN113264994A/zh active Pending
- 2015-05-28 FI FIEP15798956.7T patent/FI3155017T3/fi active
- 2015-05-28 IL IL285613A patent/IL285613B2/en unknown
- 2015-05-28 PT PT157989567T patent/PT3155017T/pt unknown
- 2015-05-28 NZ NZ757113A patent/NZ757113A/en unknown
- 2015-05-28 KR KR1020237018945A patent/KR20230084337A/ko not_active Ceased
- 2015-05-28 KR KR1020247042894A patent/KR20250007694A/ko active Pending
- 2015-05-28 US US15/314,466 patent/US9856306B2/en active Active
- 2015-05-28 NZ NZ726623A patent/NZ726623A/en unknown
- 2015-05-28 CN CN201580041790.0A patent/CN106661097A/zh active Pending
- 2015-05-28 CN CN201910116865.7A patent/CN109865142A/zh active Pending
- 2015-05-28 ES ES15798956T patent/ES2985732T3/es active Active
- 2015-05-28 EP EP24150928.0A patent/EP4397374A3/en active Pending
- 2015-05-28 BR BR112016027595-0A patent/BR112016027595B1/pt active IP Right Grant
- 2015-05-28 EP EP15798956.7A patent/EP3155017B1/en active Active
- 2015-05-28 MX MX2020000201A patent/MX384236B/es unknown
- 2015-05-28 DK DK15798956.7T patent/DK3155017T3/da active
- 2015-05-28 HU HUE15798956A patent/HUE066179T2/hu unknown
- 2015-05-28 WO PCT/US2015/033042 patent/WO2015184177A1/en not_active Ceased
-
2016
- 2016-11-17 IL IL249044A patent/IL249044B/en active IP Right Grant
-
2017
- 2017-11-21 US US15/820,127 patent/US10577405B2/en active Active
-
2020
- 2020-01-21 US US16/747,759 patent/US20200277351A1/en not_active Abandoned
- 2020-04-21 JP JP2020075470A patent/JP2020143066A/ja active Pending
- 2020-06-02 AU AU2020203609A patent/AU2020203609B2/en active Active
- 2020-06-21 IL IL275526A patent/IL275526B/en unknown
-
2022
- 2022-08-09 JP JP2022127266A patent/JP2022172128A/ja active Pending
-
2023
- 2023-02-08 AU AU2023200659A patent/AU2023200659A1/en active Pending
-
2024
- 2024-04-18 JP JP2024067692A patent/JP2024102119A/ja active Pending
- 2024-11-11 US US18/943,440 patent/US20250136656A1/en active Pending
- 2024-12-19 US US18/988,066 patent/US20250313604A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3155017T3 (fi) | Parannettuja peptidilääkkeitä insuliiniresistenssiin | |
| Li et al. | Progress of the synthesis of condensed pyrazole derivatives (from 2010 to mid-2013) | |
| JP2017519739A5 (enExample) | ||
| JP2015517488A5 (enExample) | ||
| ZA201902053B (en) | Pharmaceutical composition | |
| JP2016222689A5 (ja) | 合成ペプチド及び乾燥粉末薬剤輸送システム | |
| WO2017009236A3 (en) | New exendin-4 derivatives as selective peptidic dual glp-1 / glucagon receptor agonists | |
| MX2020006999A (es) | Farmaceuticos de peptidos mejorados para el tratamiento de nash y otros trastornos. | |
| JP2015518818A5 (enExample) | ||
| JP2018521983A5 (enExample) | ||
| ZA201902051B (en) | Pharmaceutical composition | |
| EA201700019A1 (ru) | Высокочистый оритаванцин и способ его получения | |
| PH12020550050A1 (en) | Novel acylated insulin analogues and uses thereof | |
| PH12015502100A1 (en) | Reducing the risk of autoimmune disease | |
| JP2016515123A5 (enExample) | ||
| EA202090913A1 (ru) | Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон | |
| MD20180049A2 (ro) | Compoziţie farmaceutică | |
| JP2019506840A5 (enExample) | ||
| WO2015131814A3 (zh) | [(芳氧基)(杂芳基)]甲基哌啶衍生物在制备治疗抑郁症的药物中的应用 | |
| JP2019518052A5 (enExample) | ||
| MX2015006997A (es) | Composicion farmaceutica. | |
| CY1120332T1 (el) | Μιμητικα καλσιτονινης για τη θεραπεια των ασθενειων και των διαταραχων | |
| MX2019013874A (es) | Peptidos y sus usos como agentes antivirales. | |
| WO2016008034A8 (en) | A method for modulating insulin-independent glucose transport using teneurin c-terminal associated peptide (tcap) | |
| EP2924024A3 (en) | Solid forms of lorcaserin hydrochloride |